-

Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York. Management will be available for one-on-one meetings during these conferences.

Morgan Stanley 20th Annual Global Healthcare Conference

Format: Fireside Chat
Date and Time: Tuesday, September 13th at 9:10 a.m. Eastern Time
Location: New York, New York
Webcast will be accessible through the Events page in the Investors section of the Company’s website at www.Vistagen.com.

Baird 2022 Global Healthcare Conference

Format: Fireside Chat
Date and Time: Wednesday, September 14th at 2:35 p.m. Eastern Time
Location: New York, New York

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.

Contacts

Investors:
Mark Flather
Vice President, Investor Relations
(650) 577-3617
mflather@vistagen.com

Media:
Nate Hitchings
SKDK
nhitchings@skdknick.com

Vistagen Therapeutics, Inc.

NASDAQ:VTGN

Release Summary
Vistagen to Participate in Fireside Chats at Morgan Stanley and Baird Healthcare Conferences
Release Versions
$Cashtags

Contacts

Investors:
Mark Flather
Vice President, Investor Relations
(650) 577-3617
mflather@vistagen.com

Media:
Nate Hitchings
SKDK
nhitchings@skdknick.com

Social Media Profiles
More News From Vistagen Therapeutics, Inc.

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host...

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who el...

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute trea...
Back to Newsroom